Merck/DOV Triple Reuptake Inhibitor Phase II For Depression Planned In 2006
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck and DOV continue to expect to have the first triple reuptake inhibitor for depression on the market despite a revised licensing pact that returns initial clinical trial responsibility for DOV's 21,947 compound to DOV